401 related articles for article (PubMed ID: 19636207)
1. Peptide receptor therapies in neuroendocrine tumors.
Bodei L; Ferone D; Grana CM; Cremonesi M; Signore A; Dierckx RA; Paganelli G
J Endocrinol Invest; 2009 Apr; 32(4):360-9. PubMed ID: 19636207
[TBL] [Abstract][Full Text] [Related]
2. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
3. Radiopharmaceuticals used for diagnosis and therapy of NETs.
Papachristou M
Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
[TBL] [Abstract][Full Text] [Related]
4. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
Bodei L; Pepe G; Paganelli G
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
[TBL] [Abstract][Full Text] [Related]
5. Peptide receptor radionuclide therapy with somatostatin analogues in neuroendocrine tumors.
Giovacchini G; Nicolas G; Forrer F
Anticancer Agents Med Chem; 2012 Jun; 12(5):526-42. PubMed ID: 22292758
[TBL] [Abstract][Full Text] [Related]
6. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
7. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925
[TBL] [Abstract][Full Text] [Related]
8. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
10. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
11. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES
Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217
[TBL] [Abstract][Full Text] [Related]
12. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
14. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Kjaer A; Knigge U
Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
[TBL] [Abstract][Full Text] [Related]
15. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
Narayanan S; Kunz PL
Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
[TBL] [Abstract][Full Text] [Related]
16. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
17. Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy.
Kennedy J; Chicheportiche A; Keidar Z
Semin Nucl Med; 2022 Mar; 52(2):229-242. PubMed ID: 34911637
[TBL] [Abstract][Full Text] [Related]
18. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor radionuclide therapy in neuroendocrine tumors.
Haider M; Das S; Al-Toubah T; Pelle E; El-Haddad G; Strosberg J
Endocr Relat Cancer; 2021 Mar; 28(3):R81-R93. PubMed ID: 33608483
[TBL] [Abstract][Full Text] [Related]
20. Current status and perspectives in peptide receptor radiation therapy.
Ansquer C; Kraeber-Bodéré F; Chatal JF
Curr Pharm Des; 2009; 15(21):2453-62. PubMed ID: 19601842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]